spot_img

about fansalaran

FanSalaran is a comprehensive media platform dedicated to reporting and clarifying the significant achievements of pharmaceutical companies. In collaboration with passionate and motivated young journalists, this website consistently strives to showcase the country's successes in order to inspire and encourage the hardworking individuals of this land.

FDA now providing daily updates on adverse events

The U.S. Food and Drug Administration is now providing real-time, daily publication updates on adverse event data from its reporting system.

In an effort to modernize and provide transparency on public health, the agency announced at the end of last week that adverse event data from the FDA Adverse Event Reporting System (FAERS) will be published daily. Previously, updates were published on a quarterly basis.

“People who navigate the government’s clunky adverse event reporting websites should not have to wait months for that information to become public,” FDA Commissioner Marty Makary, M.D., M.P.H., said in a statement. “We’re closing that waiting period and will continue to streamline the process from start to finish.”

The FAERS contains reports from health care professionals, consumers, and manufacturers on adverse events, serious medication errors, and product quality complaints for prescription drugs and biologics. The public can access the data on the FAERS Public Dashboard. According to the FDA, the agency receives more than 2 million reports on adverse events and medication error reports each year.

The shift to daily publication is part of “the FDA’s broader data modernization strategy to streamline all of its adverse event reporting systems and increase reporting frequency across all systems to identify safety signals faster,” the agency writes in a press release.

The FDA encourages both health care professionals and the public to report any adverse events with human medical products on the FDA MedWatch website.

Hot this week

Novo Nordisk Lowers Full-Year Profit Guidance in New CEO’s Maiden Quarter

Wegovy-maker Novo Nordisk lowered its full-year profit forecast on...

Compass Pathways to expedite launch timing of its experimental depression therapy

Drug developer Compass Pathways said on Tuesday it is...

Pharma Investment to establish manufacturing facility at SOHAR Freezone

SOHAR Port and Freezone has signed a land lease...

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Novo Nordisk and Pfizer have revised their bids for...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img